... WhatsApp

New Treatment Shows Strong Results for Moderate to Severe Ulcerative Colitis

You are here >> Home > Latest Updates > Ulcerative Colitis > New Treatment ….

EFFECTIVENESS AND SAFETY OF SELECTIVE IL-1223 RECEPTOR ANTAGONISTS IN MODERATE REVIEW, META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSISDOI 10.1590S0004-2803.24612025-056

Ulcerative colitis (UC) is a long-term condition that causes inflammation and ulcers in the colon. People with moderate to severe UC often struggle with pain, bleeding, and frequent trips to the bathroom. Finding a treatment that works well and is safe is very important.

This study looked at a newer class of medication called IL-12/23 receptor antagonists. These medicines work by calming down parts of the immune system that cause inflammation.

Researchers reviewed nine clinical trials involving thousands of patients to see how well these drugs work.

The results were clear: people who took IL-12/23 medications were more likely to feel better and have healing in the colon (called remission) than those who took a placebo.

This was true both when starting treatment and when staying on it long-term.

The drugs were also safe. During the early phase of treatment, they caused fewer serious side effects than placebo. Over time, the risk of common side effects—like headaches or mild infections—was the same between both groups.

For people living with ulcerative colitis, these findings offer hope. IL-12/23 medications may become a reliable option for those who haven’t had success with other treatments.

Rate this post
Dr. Harsh J Shah
Dr Harsh Shah - GI & HPB Oncosurgeon in India
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.